ERCC1 expression in triple negative breast cancer

Journal of B.U.ON.

Volumn 17, Issue 2, 2012, Pages 271-276

  Ozkan, C ^a   Gumuskaya, B ^a   Yaman, S ^a   Aksoy, S ^a   Guler, G ^a   Altundag, Kadri ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

ERCC1; Platinum based chemotherapy; Triple negative breast cancer

Indexed keywords

EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; CANCER PATIENT; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PROTEIN EXPRESSION; SCORING SYSTEM; TRIPLE NEGATIVE BREAST CANCER;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOENZYME TECHNIQUES; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR MARKERS, BIOLOGICAL;

EID: 84863627143     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-752.
2. Rakha EA, El-Sayed ME, Green AR et al. Prognostic markers in triple-negative breast cancer. Cancer 2007; 109: 25-32. (Pubitemid 46120191)
3. Bauer KR, Brown M, Cress RD et al. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California Cancer Registry. Cancer 2007; 109: 1721-1728. (Pubitemid 46668532)
4. Carey LA, Perou CM, Livasy CA et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006; 295: 2492-2502. (Pubitemid 43854964)
5. Dent R, Trudeau M, Pritchard KI et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007; 13: 4429-4434. (Pubitemid 47219710)
6. Arslan C, Dizdar O, Altundag K. Pharmacotherapy of triple-negative breast cancer. Expert Opin Pharmacother 2009; 10: 2081-2093.
7. Oakman C, Viale G, Di Leo A. Management of triple negative breast cancer. The Breast 2010; 19: 312-321.
8. Lehmann BD, Bauer JA, Chen X et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Ivest 2011; 121: 2750-2767.
9. Taniguchi T, Tischkowitz M, Ameziane N et al. Disruption of the Fanconi anemia-BRCA pathway in cisplatin-sensitive ovarian tumors. Nat Med 2003; 9: 568-574. (Pubitemid 36597103)
10. Turner N, Tutt A, Ashworth A. Hallmarks of "BRCAness" in sporadic cancers. Nat Rev Cancer 2004; 4: 814-819.
11. Garber JE, Richardson A, Harris LN et al. Neo-adjuvant cisplatin (CDDP) in "triple-negative" breast cancer (BC). Breast Cancer Res Treat 2006; 100(Suppl 1): S149 (abstr 3074).
12. O'Shaughnessy J, Weckstein DJ, Vukelja SJ et al. Preliminary results of a randomized phase II study of weekly irinotecan/carboplatin with or without cetuximab in patients with metastatic breast cancer. Breast Cancer Res Treat 2007; 106 (Suppl 1): S32 (abstr 308).
13. O'Shaughnessy J, Yoffe M, Osborne C et al. Triple negative breast cancer: a phase 2, multi-center, open-label, randomized trial of gemcitabine/ carboplatin (G/C), with or without BSI-201, a PARP inhibitor. Cancer Res 2009; 69 (Suppl): 194s (abstr 2120).
14. Chang HR, Gornbein JA, Chung D. Preferential pathologic complete response (pCR) by triple-negative (-) breast cancer to neoadjuvant docetaxel (T) and carboplatin (C). Proc Am Soc Clin Oncol 2008; 26: 15S (abstr 604).
15. Torrisi R, Balduzzi A, Ghisini R et al. Tailored preoperative treatment of locally advanced triple negative (hormone receptor negative and HER2 negative) breast cancer with epirubicin, cisplatin, and infusional fluorouracil followed by weekly paclitaxel. Cancer Chemother Pharmacol 2008; 62: 667-672.
16. Yi S, Uhm J, Cho E et al. Clinical outcomes of metastatic breast cancer patients with triple-negative phenotype who received platinum-containing chemotherapy. Proc Am Soc Clin Oncol 2008; 26: 15S (abstr 1008).
17. Uhm JE, Park YH, Yi SY et al. Treatment outcomes and clinicopathologic characteristics of triple-negative breast cancer patients who received platinum-containing chemotherapy. Int J Cancer 2009; 124: 1457-1462.
18. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007; 33: 9-23. (Pubitemid 46137553)
19. Martin LP, Hamilton TC, Schilder RJ. Platinum resistance: the role of DNA repair pathways. Clin Cancer Res 2008; 14: 1291-1295. (Pubitemid 351413906)
20. Bosl GJ, Motzer RJ. Testicular germ-cell cancer. N Engl J Med 1997; 337: 242-253.
21. Koberle B, Masters JR, Hartley JA et al. Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours. Curr Biol 1999; 9: 273-276. (Pubitemid 29139312)
22. Welsh C, Day R, McGurk C et al. Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines. Int J Cancer 2004; 110: 352-361. (Pubitemid 38649885)
23. Selvakumaran M, Pisarcik DA, Bao R et al. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res 2003; 63: 1311-1316. (Pubitemid 36348710)
24. Ferry KV, Hamilton TC, Johnson SW. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells: role of ERCC1-XPF. Biochem Pharmacol 2000; 60: 1305-1313.
25. Reed E, Yu JJ, Davies A et al. Clear cell tumors have higher mRNA levels of ERCC1 and XPB than other histological types of epithelial ovarian cancer. Clin Cancer Res 2003; 9: 5299-5305. (Pubitemid 37413583)
26. Olaussen KA, Dunant A, Fouret P et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006; 355: 983-991. (Pubitemid 44343542)
27. Joshi MB, Shirota Y, Danenberg KD et al. High gene expression of TS1, GSTP1 and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res 2005; 11: 2215-2221.
28. Langer R, Specht K, Becker K et al. Association of pretherapeutic expression of chemotherapy-related genes with response to neoadjuvant chemotherapy in Barrett's carcinoma. Clin Cancer Res 2005; 11: 7462-7469. (Pubitemid 41507707)
29. Metzger R, Leichman CG, Danenberg KD et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 1998; 16: 309-316. (Pubitemid 28041614)
30. Shirota Y, Stoehlmacher J, Brabender J et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001; 19: 4298-4304. (Pubitemid 33096777)
31. Warnecke-Eberz U, Metzger R, Miyazono F et al. High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer. Clin Cancer Res 2004; 10: 3794-3799. (Pubitemid 38697614)
32. Sidoni A, Cartaginese F, Colozza M et al. ERCC1 expression in triple negative breast carcinoma: the paradox revisited. Breast Cancer Res Treat 2008; 111: 569-570.
33. Wolff AC, Hammond ME, Schwartz JN et al American Society of Clinical Oncology/College of American Pathologists. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. Arch Pathol Lab Med 2007; 131: 18-43. (Pubitemid 46174133)
34. Al-Haddad S, Zhang Z, Leygue E et al. Psoriasin (S100A7) expression and invasive breast cancer. Am J Pathol 1999; 155: 2057-2066.
35. Ihemelandu CU, Leffall LD, Dewitty RL et al. Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: age-specific prevalence and survival. J Surg Res 2007; 143: 109-118. (Pubitemid 47562451)
36. Dirier A, Burhanedtin-Zincircioglu S, Karadayi B et al. Characteristics and prognosis of breast cancer in younger women. J BUON 2009; 14: 619-623.
37. Abraham J, Flanagan M, Hazard H et al. Triple-negative breast cancer in West Virginia. WV Med J 2009; 105: 54-59.
38. Ray M, Polite BN. Triple-negative breast cancers: a view from 10,000 feet. Cancer J 2010; 16: 17-22.
39. Stark A, Kapke A, Schultz D et al. Advanced stages and poorly differentiated grade are associated with an increased risk of HER2/neu positive breast carcinoma only in White women: findings from a prospective cohort study of African-American and White-American women. Breast Cancer Res Treat 2008; 107: 405-414. (Pubitemid 351172112)
40. Thike AA, Cheok PY, Jara-Lazaro AR et al. Triple-negative breast cancer: clinicopathological characteristics and relationship with basal-like breast cancer. Mod Pathol 2010; 23: 123-133.
41. Leong CO, Vidnovic N, DeYoung MP et al. The p63/p73 network mediates chemosensitivity to cisplatin in a biologically defined subset of primary breast cancers. J Clin Invest 2007; 117: 1370-1380. (Pubitemid 46718425)